Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247309 · ClinicalTrials.gov registry record · Phase 1
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
A Phase 1 study of Cancer and Solid Tumor, sponsored by Immatics US.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT03247309: Completed Phase 1 study of Cancer and Solid Tumor, sponsored by Immatics US.
NCT03247309 is a Phase 1 study of Cancer and Solid Tumor that has completed, run by Immatics US. The registered enrollment target is 7 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247309, a Phase 1 study of Cancer and Solid Tumor, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
Conditions Studied
Interventions
- BIOLOGICAL IMA201 Product
- DIAGNOSTIC_TEST IMADetect®
Study Locations (5)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- University of Texas MD Anderson Cancer Center - Houston
North Rhine-Westphalia
- Universitätsklinikum Bonn, Venusberg-Campus 1 - Bonn
Saxony
- Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74 - Dresden
Other
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 1 |
What the finished NCT03247309 record still lists
NCT03247309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which IMA201 Product is the first listed.
NCT03247309 lists 5 locations in 5 states (Pennsylvania, Texas, North Rhine-Westphalia).
Frequently Asked Questions
What is clinical trial NCT03247309 about?
NCT03247309 is a clinical study titled "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)". The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
What is the current status of trial NCT03247309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-12-19. Estimated completion is 2023-09-18.
What conditions does trial NCT03247309 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Refractory Solid Tumors, Recurrent Solid Tumors.
What interventions are being tested in trial NCT03247309?
The interventions under investigation include: IMA201 Product (BIOLOGICAL), IMADetect® (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03247309?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03247309 being conducted?
This trial has 5 study locations across Pennsylvania, Texas, North Rhine-Westphalia, Saxony. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03247309's enrollment target sits among peer trials
7 609th of 615 higher than 5 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI